Researchers in US give first shot to person in experimental COVID-19 vaccine test

Image
ANI US
Last Updated : Mar 17 2020 | 1:15 AM IST

As coronavirus cases continue to shoot up across the globe, researchers in the US gave first shot to the first person in a test of an experimental COVID-19 vaccine on Monday.

According to a report by the Associated Press (AP), scientists at the Kaiser Permanente Washington Research Institute in Seattle begin an 'anxiously awaited first-stage study of a potential COVID-19 vaccine developed in record time'.

Forty-three-year-old Jennifer Haller of Seattle, an operations manager at a tech company, received the injection inside an exam room.

Haller, the mother of two teenagers, termed it an "amazing opportunity" for her to "do something".

The said 'vaccine', codenamed mRNA-1273, was developed by the National Institutes of Health (NIH) and Massachusetts-based biotechnology company Moderna Inc.

More than 1,50,000 people have been infected worldwide by the virus which originated in China last December and has claimed the lives of over 6,500 people.

"We are team coronavirus now. Everyone wants to do what they can in this emergency," Kaiser Permanente study leader Dr Lisa Jackson was quoted as saying on the eve of the experiment.

Jackson said that from not even knowing that coronavirus was out there to have any vaccine in testing in about two months is 'unprecedented'. She, although, said that it is not at this stage where it would be "possible or prudent" to give it to the general population.

The tests came amid worldwide attempts to develop the vaccine for the deadly virus.

However, these vaccines are unlikely to be available for widespread use anytime for 12 to 18 months, said Dr Anthony Fauci of the NIH.

Finding a vaccine "is an urgent public health priority," Dr Fauci was quoted as saying.

According to the AP report, most of the vaccine research underway targets a protein aptly named "spike" that studs the surface of the new coronavirus and lets it invade human cells.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 17 2020 | 1:00 AM IST

Next Story